The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for tocilizumab (Roche Products Pty Limited)
Active ingredients
tocilizumab
Sponsor
Date of review outcome
Lapse date
Type
Provisional approval
Indication
Coronavirus disease 2019 (COVID-19) (IV formulation only) for the treatment of coronavirus disease 2019 (COVID-19) in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation
Therapeutic area
Infectious diseases